CD244 and plasma cell myeloma: Elotuzumab, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies, and ALDESLEUKIN, an antineoplastic agent, have also been identified as drugs targeting CD244.